Trinity Delta Lighthouse: Bonesupport
Trinity Delta view: Bonesupport has made major inroads in implementing its growth strategy for CERAMENT as it seeks to affect a paradigm shift in the way that bone voids are treated. The antibiotic eluting CERAMENT G & V have gained commendable traction and become the option of choice for many influential surgeons in the markets where they are available. A similar clinical uptake in the commercially important US market would be transformative for Bonesupport.De Novo filing with the FDA in April, means that first CERAMENT G approval in chronic osteomyelitis could occur in late 2020, with a potential launch in early 2021. FDA approval in the trauma indication is contingent on data from the FORTIFY study, with pending FDA discussions to determine the final stage of the study. This fund raise allows management to plan and execute a more ambitious North American launch programme.
Our valuation and forecasts will, as is usual, be suspended until we have revised our models; we will aim to do as soon as is practicable. For context, our prior valuation was SEK2.27bn or SEK43.3/share.
Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.